ARTICLE | Clinical News
Blueprint Medicines preclinical data
April 21, 2014 7:00 AM UTC
In mouse xenograft models of fibroblast growth factor 19 (FGF19) amplified and FGF19 overexpressing HCC, oral BLU9931 led to sustained, dose-dependent tumor regression. Data were presented at the Ame...